FY2025 · period end Dec '25 · from the 10-K filed Mar 31, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.00B | $0.00B | $0.00B | — | — |
| Gross Profit | $0.00B | $0.00B | $0.00B | — | — |
| Operating Income | negative: -$0.01B | negative: -$0.00B | negative: -$0.01B | negative: -$0.01B | negative: -$0.00B |
| Net Income | negative: -$0.01B | negative: -$0.01B | negative: -$0.02B | negative: -$0.01B | negative: -$0.00B |
| EPS (Diluted) | negative: -$4.83 | negative: -$14.56 | negative: -$1.46 | negative: -$5.47 | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.00B | $0.00B | $0.06B | $0.00B | $0.16B |
| Total Liabilities | $0.01B | $0.01B | $0.04B | $0.01B | $0.01B |
| Stockholders' Equity | negative: -$0.01B | negative: -$0.00B | $0.02B | negative: -$0.04B | negative: -$0.03B |
| Cash & Equivalents | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.00B | negative: -$0.00B | negative: -$0.01B | negative: -$0.00B | negative: -$0.00B |
| Capital Expenditures | $0.00B | — | $0.00B | $0.00B | — |
| Free Cash Flow | negative: -$0.00B | — | negative: -$0.01B | negative: -$0.00B | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 57.2% | 87.4% | — | — | — |
| Operating Margin | negative: -3.7% | negative: -9933.8% | — | — | — |
| Net Margin | negative: -3.6% | negative: -20605.5% | — | — | — |
| Return on Equity | 117.7% | 220.0% | negative: -62.4% | 24.0% | 1.1% |
| Return on Assets | negative: -359.6% | negative: -31.7% | negative: -47.0% | negative: -11.5% | negative: -0.2% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-257520 | Jun 1, 2026 | Jun 4, 2026 | Jun 4, 2026 20:30 UTC | EDGAR |
| 10-Q | 0001193125-26-224428 | Mar 31, 2026 | May 15, 2026 | May 14, 2026 21:53 UTC | EDGAR |
| 10-K | 0001193125-26-134698 | Dec 31, 2025 | Mar 31, 2026 | Mar 31, 2026 20:30 UTC | EDGAR |
| 8-K | 0001193125-26-109472 | Mar 13, 2026 | Mar 17, 2026 | Mar 17, 2026 12:30 UTC | EDGAR |
| 8-K | 0001193125-25-317638 | Dec 8, 2025 | Dec 12, 2025 | Dec 12, 2025 21:30 UTC | EDGAR |
| 10-Q | 0001193125-25-283127 | Sep 30, 2025 | Nov 14, 2025 | Nov 14, 2025 21:30 UTC | EDGAR |
| 8-K | 0001193125-25-272538 | Nov 3, 2025 | Nov 7, 2025 | Nov 7, 2025 22:00 UTC | EDGAR |
| 8-K | 0000950170-25-114421 | Sep 10, 2025 | Sep 12, 2025 | Sep 12, 2025 16:00 UTC | EDGAR |
Direct links to SEC EDGAR. XAGE has additional filings available on the SEC site.
6 numbers Longevity Health Holdings, Inc. later changed — same XBRL tag, both filings linked.
Operating Income (Loss)·Q3 2023
Major restatementwas-$5.1M
Revised up in a 10-Q.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q3 2023
Major restatementwas-$11.5M
Revised up in a 10-Q.
Net Cash Provided by (Used in) Operating Activities·Q3 2024
Major restatementwas-$3.6M
Revised up in a 10-Q.
Net Cash Provided by (Used in) Operating Activities·FY 2024
Major restatementwas-$4.4M
Revised up in a 10-K.
Net Cash Provided by (Used in) Operating Activities·Q3 2023
Notable restatementwas-$5.2M
Revised up in a 10-Q.
Operating Expenses·Q3 2023
Major restatementwas$7.3M
Revised down in a 10-Q.
XAGE is not the only one.
See every restatement we've found across the market — or get an alert the next time XAGE revises a number.
Restatements are detected by comparing every vintage of a fact across all of Longevity Health Holdings, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows XAGE's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Longevity Health Holdings, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on XAGE yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on XAGE and publish the result to your public profile.
Ask about Longevity Health Holdings, Inc.
Continue in Workspace — cited answers on XAGE, a thesis you can score, or an alert on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs